NAFLD

Oct 09, 2024

Nonalcoholic steatohepatitis (NASH), also referred to as Metabolic Dysfunction-Associated Steatohepatitis (MASH), has rapidly become a significant contributor to liver disease in the United States. The NASH market is growing at a substantial rate, driven by the increasing prevalence of the condition. According to t...

Sep 04, 2024

Nonalcoholic Steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by liver inflammation and damage due to fat accumulation. Unlike simple fatty liver, NASH can progress to serious conditions such as fibrosis, cirrhosis, and liver failure. This chronic liver disease is i...

May 22, 2019

NASH market share of off label therapies, it will keep on experiencing a steady growth until a standard approved therapy enters the NASH treatment market. Non-alcoholic fatty liver disease (NAFLD), is the most common group of conditions in which there is an excess fat accumulation in the liver in people who i...

Mar 17, 2017

Fatty liver disease is the common form of Non-alcoholic fatty liver disease (NAFLD), whereas very extreme form of NAFLD is termed as Non-alcoholic Steatohepatitis (NASH). NASH is characterized by deposition of fat with 5%-10% of liver weight in liver of people who drink very little or no drinking leading to inflamma...